DK0902780T3 - Kvaternære cytofectiner - Google Patents

Kvaternære cytofectiner

Info

Publication number
DK0902780T3
DK0902780T3 DK97920200T DK97920200T DK0902780T3 DK 0902780 T3 DK0902780 T3 DK 0902780T3 DK 97920200 T DK97920200 T DK 97920200T DK 97920200 T DK97920200 T DK 97920200T DK 0902780 T3 DK0902780 T3 DK 0902780T3
Authority
DK
Denmark
Prior art keywords
quaternary
lipids
cytofectins
transfective
derivatized
Prior art date
Application number
DK97920200T
Other languages
Danish (da)
English (en)
Inventor
Carl J Wheeler
Original Assignee
Vical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vical Inc filed Critical Vical Inc
Application granted granted Critical
Publication of DK0902780T3 publication Critical patent/DK0902780T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK97920200T 1996-04-09 1997-04-08 Kvaternære cytofectiner DK0902780T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/629,965 US5994317A (en) 1996-04-09 1996-04-09 Quaternary cytofectins
PCT/US1997/005757 WO1997037966A1 (en) 1996-04-09 1997-04-08 Quaternary cytofectins

Publications (1)

Publication Number Publication Date
DK0902780T3 true DK0902780T3 (da) 2002-02-11

Family

ID=24525211

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97920200T DK0902780T3 (da) 1996-04-09 1997-04-08 Kvaternære cytofectiner

Country Status (9)

Country Link
US (1) US5994317A (ja)
EP (1) EP0902780B1 (ja)
JP (1) JP4031045B2 (ja)
AT (1) ATE207874T1 (ja)
CA (1) CA2251169C (ja)
DE (1) DE69707870T2 (ja)
DK (1) DK0902780T3 (ja)
ES (1) ES2166540T3 (ja)
WO (1) WO1997037966A1 (ja)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
EP0500799B1 (en) 1989-11-16 1998-01-14 Duke University Particle mediated transformation of animal skin tissue cells
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US7105574B1 (en) 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
EP1987845B1 (en) 1997-11-20 2012-03-21 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor.
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
ATE272410T1 (de) * 1999-03-26 2004-08-15 Vical Inc Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
AU5702699A (en) * 1999-09-03 2001-04-10 Procter & Gamble Company, The Cationic alkyl alkoxylate derivatives
WO2001080897A2 (en) * 2000-04-21 2001-11-01 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
KR100381512B1 (ko) 2000-09-21 2003-04-26 굿젠 주식회사 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 용도
EP1349577A2 (en) * 2000-11-06 2003-10-08 Asilomar Pharmaceuticals, Inc. Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins
WO2002098465A2 (en) * 2001-06-07 2002-12-12 Celator Technologies, Inc. Cell penetrating therapeutic agents
EP3100719A3 (en) 2002-05-15 2017-02-22 California Pacific Medical Center Delivery of nucleic acid-like compounds
AU2003278776A1 (en) * 2002-09-10 2004-04-30 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
EP1578193A4 (en) * 2002-12-23 2011-06-15 Vical Inc FREEZING PROCESS FOR NUCLEIC ACID / BLOCK COPOLYMER / CATION SIDE COMPLEXES
WO2004060363A1 (en) * 2002-12-23 2004-07-22 Vical Incorporated Method for producing sterile polynucleotide based medicaments
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
BRPI0515264B1 (pt) 2004-09-13 2018-12-18 Genzyme Corp proteína de fusão de acordo com fórmula x-y-z, composição, molécula de ácido nucleico, seus usos e método de multimerização de um polipeptídeo x
WO2006060723A2 (en) * 2004-12-03 2006-06-08 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
JP5902616B2 (ja) * 2010-04-28 2016-04-13 協和発酵キリン株式会社 カチオン性脂質
JP5902617B2 (ja) * 2010-04-28 2016-04-13 協和発酵キリン株式会社 カチオン性脂質
JP2013095755A (ja) * 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd カチオン性脂質
HRP20211424T2 (hr) * 2012-06-08 2022-02-18 Nitto Denko Corporation Lipidi za formulacije namijenjene unosu terapijskog sredstva
JP6910947B2 (ja) 2015-03-24 2021-07-28 協和キリン株式会社 核酸含有脂質ナノ粒子
CA3089826A1 (en) * 2018-02-01 2019-08-08 Trustees Of Tufts College Lipid-like nanocomplexes and uses thereof
WO2020018700A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2368208A (en) * 1940-12-16 1945-01-30 Emulsol Corp Chemical compounds and method of preparing same
US3265719A (en) * 1959-12-28 1966-08-09 American Cyanamid Co Betaines
DE2651898A1 (de) * 1976-11-13 1978-05-18 Hoechst Ag Waescheweichspuelmittel
US5049386A (en) * 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
DE3618517A1 (de) * 1985-06-04 1986-12-04 Lion Corp., Tokio/Tokyo Emulgiermittel zur emulsionspolymerisation
US5068431A (en) * 1987-08-31 1991-11-26 Witco Corporation Methods of making new surface active compounds
US4864060A (en) * 1987-08-31 1989-09-05 Witco Corporation Surface active compounds, methods for making same and uses thereof
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
JPH03181597A (ja) * 1989-12-12 1991-08-07 Bridgestone Corp 電気粘性流体
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
DE4241983C1 (de) * 1992-12-12 1994-03-24 Messer Griesheim Gmbh Schutzgas für das Lichtbogenschweißen von Aluminium
US5364324A (en) * 1992-12-14 1994-11-15 Boettiger Jr Walter W Exercise device
US5753613A (en) * 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells

Also Published As

Publication number Publication date
US5994317A (en) 1999-11-30
WO1997037966A1 (en) 1997-10-16
CA2251169A1 (en) 1997-10-16
EP0902780B1 (en) 2001-10-31
JP4031045B2 (ja) 2008-01-09
DE69707870T2 (de) 2002-07-11
EP0902780A1 (en) 1999-03-24
JP2000508642A (ja) 2000-07-11
ATE207874T1 (de) 2001-11-15
CA2251169C (en) 2006-12-19
DE69707870D1 (de) 2001-12-06
ES2166540T3 (es) 2002-04-16

Similar Documents

Publication Publication Date Title
ES2166540T3 (es) Citofectinas cuaternarias.
WO1997019675A3 (en) Complex cationic lipids
HK1016886A1 (en) Drug delivery system for two or more active substances
EP1080231A4 (en) MULTIMOLECULAR DEVICES, SYSTEMS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES AND SELECTION OF INDIVIDUAL MOLECULES
ATE332918T1 (de) Neoglycoproteine
FR2760193B1 (fr) Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
HK1037133A1 (en) Conjugates for treating inflammatory disorders and associated tissue damage
AU7796198A (en) Novel acoustically active drug delivery systems
PT1137670E (pt) Processo de ligacao transversal de polissacaridos carboxilados
GB2335357A (en) Chitosan-gelatin A microparticles
BR9804500B1 (pt) derivado de amida, referida composição farmacêutica e agente terapêutico.
DE69815075D1 (de) Dimere kationische lipide auf dicystinbasis
HK1012556A1 (en) Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
MX9804969A (es) Dispositivo de distribucion de farmaco.
NZ335799A (en) Improvements in or relating to diagnostic/therapeutic agents
EP0904100A4 (en) ADMINISTRATION OF BIOLOGICALLY ACTIVE MOLECULES, FACILITATED BY A LIGAND RECEPTOR
HK1020523A1 (en) Uniform drug delivery therapy
DK1044064T3 (da) Overtrækningsindretning til granula til indtagelse ad oral vej
GB9724143D0 (en) Pharmaceutical conjugate
NZ326436A (en) Ligand directed enzyme prodrug therapy for tumours using ligands that recognise and bind tumour receptors
ATE419833T1 (de) Modulares zielgerichtetes liposomales verabreichungssytem
MX213693B (es) Polimero cationico.
ATE271032T1 (de) Amphiphile polyamin verbindungen
PL341597A1 (en) Agent containing a combination of active substances
DE59505895D1 (de) Verteiler-bzw. Zustellerwagen